ASH 2024 | Real-world retrospective analysis of outcomes with BV maintenance after autoSCT in Hodgkin lymphoma

So this is another poster presentation that is going to be done on behalf of the Lymphoma Working Party of the EBMT together with other national groups and it’s probably the biggest real-world evidence on the use of brentuximab vedotin as consolidation or maintenance therapy after autologous stem cell transplantation in patients that have high-risk disease in terms of disease relapse after the autologous stem cell transplant. So we were able to collect patients that were reported to the EBMT registry together with patients that were collected also in a retrospective fashion by the Lysarc group, the Spanish GELTAMO group, also the Italian group, and also we are collecting the Turkish experience. The objective is to provide real-world evidence on the efficacy and the toxicity profile of brentuximab vedotin in this setting, taking into consideration that apart from a smaller experience, the information that we have comes from the AETHERA trial which was published several years ago and it was a Phase III randomized clinical trial looking at brentuximab vedotin in this specific setting. So in this retrospective analysis, we are able to replicate the potential beneficial effect of using BV in the real world as consolidation therapy in patients with high-risk classical Hodgkin’s lymphoma that have undergone autologous stem cell transplant because of relapsed/refractory disease and we have also been able to replicate the toxicity profile in the real-world.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.